5-[1-fluoro-3-hydroxy-6-(3-hydroxy-3-methylbutoxy)-2-naphthyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one

ID: ALA5089047

PubChem CID: 155103504

Max Phase: Preclinical

Molecular Formula: C17H19FN2O6S

Molecular Weight: 398.41

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CC(C)(O)CCOc1ccc2c(F)c(N3CC(=O)NS3(=O)=O)c(O)cc2c1

Standard InChI:  InChI=1S/C17H19FN2O6S/c1-17(2,23)5-6-26-11-3-4-12-10(7-11)8-13(21)16(15(12)18)20-9-14(22)19-27(20,24)25/h3-4,7-8,21,23H,5-6,9H2,1-2H3,(H,19,22)

Standard InChI Key:  MIHPKSTWQYHSSK-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
   24.7427  -24.3672    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.5352  -24.5818    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   25.3248  -23.7882    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.9265  -25.8240    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.9254  -26.6436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.6334  -27.0525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.6317  -25.4152    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3403  -25.8204    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3410  -26.6394    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0496  -27.0465    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.7578  -26.6357    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.7531  -25.8136    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0440  -25.4102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.4574  -25.3983    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.2060  -25.7261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.7491  -25.1155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.3362  -24.4102    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.5623  -25.1959    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.0397  -24.5930    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   25.4671  -27.0415    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.2174  -27.0516    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   20.5100  -26.6424    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.8020  -27.0505    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.0946  -26.6413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.3865  -27.0494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.0952  -25.8241    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.3827  -26.2327    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  9  2  0
  8  7  2  0
  7  4  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13  8  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17  2  1  0
  2 14  1  0
 12 14  1  0
 16 18  2  0
 13 19  1  0
 11 20  1  0
  5 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 24 26  1  0
 24 27  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5089047

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 398.41

Molecular Weight (Monoisotopic): 398.0948

AlogP: 1.41

#Rotatable Bonds: 5

Polar Surface Area: 116.17

Molecular Species: ACID

HBA: 6

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 3.77

CX Basic pKa: ┄

CX LogP: 0.54

CX LogD: -0.45

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.70

Np Likeness Score: -0.04

References

1. Abdel-Magid AF..  (2022)  The Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic Diseases.,  13  (1.0): [PMID:35059117] [10.1021/acsmedchemlett.1c00678]

Source

Source(1):

• Scientific Literature